T. Rowe Price Launches Active ETF Targeting Biotech Innovation (TDNA)

T. Rowe Price launched the Biotech ETF (TDNA), an actively managed strategy targeting companies developing and commercializing innovative therapies. The fund normally invests at least 80% of assets in biotechnology companies and is expected to hold roughly 60–120 stocks across market capitalizations and geographies. Its bottom-up approach draws on scientific, clinical, regulatory, competitive and commercial research to identify companies with attractive long-term prospects. Unlike rules-based biotech ETFs, portfolio exposures can change as clinical trial results, regulatory decisions and other developments reshape individual companies’ risk and return profiles.